NEW INSIGHT IN NEW INSIGHT IN HEPATITIS B IN CHILDRENHEPATITIS B IN CHILDREN
Mei-Hwei Chang , M.D.Mei-Hwei Chang , M.D.Department of Pediatrics,Department of Pediatrics,National Taiwan University National Taiwan University
Hospital,Hospital,Taipei, TAIWANTaipei, TAIWAN
Chang MHReplication Cycle of HBV
Chang MH
EPIDEMIOLOGYEPIDEMIOLOGY
Chang MH
Prevalence of Chronic Prevalence of Chronic Hepatitis B Hepatitis B
HBsAg Prevalence
> 8% - High 2-8% - Intermediate< 2% - Low
Immigration numbers summed by continent from 1996-2002
~ 2 million Asians
~ 400,000South Americans
~ 350,000 Africans
~ 930, 000 Europeans
Centers for Disease Control. Hepatitis B fact sheet. Available at: http://www.cdc.gov/hepatitis. Accessed January 31, 2006. Mahoney FJ. Clin Microbiol Rev. 1999;12:351-366. Hepatitis B Foundation. Hepatitis B statistics. Available at: http://www.hepb.org/hepb/statistics.org. Accessed January 31, 2006.
Chang MH
NATURAL HISTORY NATURAL HISTORY OF OF HEPATITIS VIRUS HEPATITIS VIRUS
INFECTIONINFECTION
Chang MH
Natural History of Hepatitis B
Chang MH
FACTORS AFFECTING THE FACTORS AFFECTING THE CLINICAL COUSE OF CLINICAL COUSE OF HEPATITIS VIRUS INFECTIONHEPATITIS VIRUS INFECTION
• Host Host Age of Infection Age of Infection
• VirusVirus : : Genotype Genotype Mutants / VariantsMutants / Variants
• Route of InfectionRoute of Infection • Other FactorsOther Factors
Chang MH
- Perinatal Transmission- Perinatal Transmission
- Childhood Infection- Childhood Infection
- Adolescent/Adult Onset - Adolescent/Adult Onset
DiseaseDisease
Age of Infection and OutcomeAge of Infection and Outcome
Chang MH
HBV GENOTYPE AND HBV GENOTYPE AND HBeAg HBeAg
SEROCONVERSIONSEROCONVERSION
Chang MH
Kao JH, Chen DS. Current Hepatitis Report 2006 (in press).Kao JH, Chen DS. Current Hepatitis Report 2006
Worldwide Distribution of HBV Genotypes. The Size of the Capitals indicates the Relative Prevalence of the Genotypes
Chang MH
0%
20%
40%
60%
80%
100%
HBeAg(+/+) HBeAg(+/-) Anti-HBe(+) HCC
A
B+C
B→ C
C→ B
Genotype C
Genotype B
No. of Children with Chronic HBV Infection 160 238 62 26
HBV GenotypeFollow-up
B B B B
C C C
C
Ni YH, Chang MH, et al. Gastroenterology 2004 ;127:1733-8.
Chang MH
Age in Years
HB
eAg
Ser
opos
itiv
ity
Genotype C
Genotype B
Ni YH, Chang MH, et al. Gastroenterology 2004 ;127:1733-8.
Genotype C
Genotype B
Chang MH
HBV Genotype and Clinical HBV Genotype and Clinical Course in ChildrenCourse in Children
• Genotype C Delays HBeAg Genotype C Delays HBeAg Seroconversion in Chronic HBV Seroconversion in Chronic HBV Infection in ChildrenInfection in Children
• Genotype Changes : RareGenotype Changes : Rare
• Genotype B Dominates in Genotype B Dominates in Children with Chronic HBV Children with Chronic HBV Infection and HCC in TaiwanInfection and HCC in Taiwan
Ni YH, Chang MH, et al. Gastroenterology 2004 ;127:1733-8.
Chang MH
HBV VARIANTS / HBV VARIANTS / MUTANTS MUTANTS
Chang MH
A Point Mutation at Codon 28 ( Nucleotide 1896) of HBV Precore Gene
TGG TAG(Tryptophan) (Stop Codon)
Leading to HBeAg Negative Strains
Chang MH
CHANGES OF HBV PRECORE GENE CHANGES OF HBV PRECORE GENE 1896 IN 80 HBsAg CARIER 1896 IN 80 HBsAg CARIER CHILDRENCHILDREN
0%10%20%30%40%50%60%70%80%90%
100%
1st HBeAgPositive
Last HBeAgPositive
1st HBeAgNegative
Last HBeAgNegative
PCR Neg.
Mutant Only
Mixed
Wild Only
Chang MH, et al. J Hepatol. 1998 ;28:915-
22.
Chang MH
Peak ALT levels during follow-up in 3 Peak ALT levels during follow-up in 3 groups with different patterns of HBV groups with different patterns of HBV precore 1896precore 1896
Peak ALT Peak ALT Group 1Group 1 Group 2 Group 2 Group 3Group 3 Total Total(IU/l) (IU/l) ((n=n=37)37) ( (n=n=22) 22) ((n=n=21)21) ( (n=n=80)80)
Mean Mean 136 136 179 179 209 209 167 167+- SD +- SD +- 149+- 149 +- 141 +- 141 +- 195+- 195 +-161 +-161
Group 1: Wild type throughout the whole Group 1: Wild type throughout the whole course.course.
Group 2: Mutant after HBe seroconversionGroup 2: Mutant after HBe seroconversionGroup 3: Mutant before HBe seroconversion.Group 3: Mutant before HBe seroconversion.• ALT levels between groups, ALT levels between groups, p=p=0.07.0.07.
Chang MH, et al. J Hepatol 1998; 28: 915-22.
Chang MH
Comparisons of HBV Core Gene Between Comparisons of HBV Core Gene Between 31 Chronic Carriers and 12 HCC Children31 Chronic Carriers and 12 HCC Children
Codon Mutated Cases (No.) in HCC
Mutated Cases (No.) in Chronic carrier
Mutations P value
Precore 28 58% (7) 52.2% (12) WX 0.73
Core 21 8% (1) 21.7% (5) SP or A 0.32
Core 65 33% (4) 17.3% (4) LW or V 0.29
Core 74 33% (4) 0 SG 0.0032
Core 87 33% (4) 0 SG 0.0032
Core 131 8% (1) 0 AD 0.16
Core 143 33% (4) 4.3% (1) LP 0.015
Core 147 8% (1) 21.6% (5) TC or S 0.32
Core 159 42% (5) 0 RS 0.0006
Core 182 42% (5) 4.3% (1) QX 0.0035
Ni YH, et al. Gut 2003;52:122-5
Chang MH
Comparisons of HBV Core Gene Comparisons of HBV Core Gene Between Between 31 Chronic Carriers and 12 HCC 31 Chronic Carriers and 12 HCC ChildrenChildren - SUMMARY - SUMMARY
• Core gene codon 21, 65, and 147 were Core gene codon 21, 65, and 147 were the commonest mutation sites in the commonest mutation sites in children with chronic HBV infection. All children with chronic HBV infection. All were located in HBcAg epitopes of CTL. were located in HBcAg epitopes of CTL.
• Codon 74, 87, and 159 mutations are Codon 74, 87, and 159 mutations are found in HCC children, but not in the found in HCC children, but not in the chronic infection group.chronic infection group.
Ni YH, et al. Gut 2003;52:122-5
Chang MH
DISCUSSIONDISCUSSION
•These mutations may help These mutations may help HBV to escape host HBV to escape host immune pressure, to immune pressure, to expand viral proteins, and expand viral proteins, and finally bring in the cancer finally bring in the cancer development. development.
Chang MH
TREATMENT TREATMENT OF OF
HEPATITIS BHEPATITIS B
CURRENT THERAPY FOR CURRENT THERAPY FOR HEPATITIS B IS NOT HEPATITIS B IS NOT SATISFACTORY SATISFACTORY
Chang MH
CURRENT GOAL OF CURRENT GOAL OF ANTIVIRAL ANTIVIRAL THERAPY FOR HEAPTITIS B THERAPY FOR HEAPTITIS B
•Reduction of Viral Reduction of Viral ReplicationReplication
•Amelioration of Amelioration of Hepatic DysfunctionHepatic Dysfunction
Chang MH
HBV Antiviral Therapy Is HBV Antiviral Therapy Is Not Recommended inNot Recommended in
• HBeAg Negative & Normal ALT HBeAg Negative & Normal ALT Subjects : Relatively Stable Subjects : Relatively Stable Course with Low Rate of Course with Low Rate of Progression.Progression.
• HBeAg Positive & Normal ALT HBeAg Positive & Normal ALT Subjects : May Progress , But Subjects : May Progress , But No Effective Therapy.No Effective Therapy.
Chang MH
CURRENT APPROVED THERAPY CURRENT APPROVED THERAPY FOR HEPATITIS B FOR HEPATITIS B
• InterferonInterferon Interferon –Interferon –αα** Pegylated Interferon-Pegylated Interferon-αα
• Nucleoside AnalogNucleoside Analog Lamivudine*Lamivudine* Adefovir Adefovir Entecavir Entecavir
* Approved for use in children
Chang MH
Effects of interferon in Effects of interferon in childhood hepatitis Bchildhood hepatitis B
Place &Place & ALT HBeAg Clearance (%) ALT HBeAg Clearance (%)
Authors at RxAuthors at Rx Control IFN Control IFN RxRx
Barbera no limit 14% (5/37) 26% (10/39)Barbera no limit 14% (5/37) 26% (10/39)
Gregorio > 1.5xN 13% (4/31) 38% (24/64)Gregorio > 1.5xN 13% (4/31) 38% (24/64)
Lai no limit 0% (0/30) 8% (5/60)Lai no limit 0% (0/30) 8% (5/60)
Tsai, Hsu > 2xN 38% (5/13) 44% (8/18)Tsai, Hsu > 2xN 38% (5/13) 44% (8/18)
Sokal > 2xN 11% (8/74) 26% (18/70)Sokal > 2xN 11% (8/74) 26% (18/70)
Meta-Ana no limit 11% (12/113) 23%(29/126)Meta-Ana no limit 11% (12/113) 23%(29/126)
Chang MH
Efficacy according to baseline Efficacy according to baseline ALTALT
0
10
20
30
40
50
60
> 1xULN > 2xULN > 5xULN
Baseline ALT
Placebo (n=95) Lamivudine (n=191)
11/88
43/1839/58
33/97
4/17
8/16
50%
24%
34%
16%
23%
13%
% complete virologic response
(HBeAg(-), HBV DNA(-)
Jonas et al, N Engl J Med 2002; 346: 1706.
Chang MH
LamivudineLamivudine p paediatric phase 3 aediatric phase 3 study study (NUC30903)(NUC30903)
Placebo (n=97)Placebo (n=97)
Wk 52Wk 52Baseline
No treatment (n=63)No treatment (n=63)
One year placebo One year placebo controlled studycontrolled study
Two yearTwo yearfollow-on studyfollow-on study
Lamivudine 3 mg/kg (n=191)Lamivudine 3 mg/kg (n=191)
Lamivudine 3mg/kgLamivudine 3mg/kg
HBeAg-ve
HBeAg+veTreatment (n=213)
89% Durability of response at month 36
Sokal E et al. Hepatology. 2006; 43: 225-32.
Chang MH
Long term lamivudine therapy Long term lamivudine therapy for children with HBeAg+ve CHB for children with HBeAg+ve CHB (2)(2)
• Virologic response in the treatment armVirologic response in the treatment arm 21%21% after 12 + 24 months of Rx (n=133) after 12 + 24 months of Rx (n=133) 30%30% after 0 + 24 months Rx (n=77) after 0 + 24 months Rx (n=77) * VR = loss of HBeAg loss and HBV DNA * VR = loss of HBeAg loss and HBV DNA
• The incidence of YMDD mutationsThe incidence of YMDD mutations was was 64%64% (66/103) after 12 + 24 months of (66/103) after 12 + 24 months of
lamivudinelamivudine 49%49% (34/70) after 0 + 24 months of (34/70) after 0 + 24 months of lamivudine lamivudine
Sokal E et al. Hepatology. 2006; 43: 225-32.
Chang MH
PREVENTION OF PREVENTION OF VIRAL VIRAL
HEPATITISHEPATITIS
Chang MH
Chang MH
IMPORTANT IMPORTANT TRANSMISSION ROUTE IN TRANSMISSION ROUTE IN HYPERENDEMIC AREAS : HYPERENDEMIC AREAS : MOTHER TO CHILD MOTHER TO CHILD
EFFECTIVE PREVENTION EFFECTIVE PREVENTION
OF HEPATITIS B :OF HEPATITIS B :
VACCINATION IN VACCINATION IN INFANCY INFANCY
Chang MH
HEPATITIS B VACCINATION HEPATITIS B VACCINATION AND AND CONTROL OF HEPATITIS B CONTROL OF HEPATITIS B RELATED LIVER DISEASES RELATED LIVER DISEASES
•Acute /Fulminant Acute /Fulminant HepatitisHepatitis
•Chronic Hepatitis Chronic Hepatitis
•Liver Cirrhosis ?Liver Cirrhosis ?
•Hepatocellular CarcinomaHepatocellular Carcinoma
Chang MH
Annual mortality rate of fulminant hepatitis per100,000 infants in Taiwan
0
2
4
6
8
1970 1975 1980 1985 1990 1995 2000
year
Universal HBV Vaccination and Universal HBV Vaccination and Decreased Decreased Mortality from Fulminant Hepatitis Mortality from Fulminant Hepatitis in in Infants in Taiwan Infants in Taiwan
Universal HBV Vaccination July 1984Universal HBV Vaccination July 1984
Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. J Pediatr. 2001;139:349-52.
*The average mortality rate per 105 infantsMortality Ratio: 3.2 (p <0.001)
1974-1984: 5.36*
1985-1998: 1.71*
Chang MH
Incidence Rate Ratios (IRR) of HBV-Positive v.s. -Negative FHF in 15 Years of the Universal Vaccination Program (Chen et al. Hepatology 2004 ;39:58-63) Year 1985~99,Case
No. (Incidence per 10 5)
P-ValueHBV(+) FHF 43
<1 Yr 33 (0.74) 54.2[26.1, 123.2]
<0.01
1-15 Yr 10 (0.014)
1-15 Yr <0.01
IRR(1 v.s. 1-15Y)[95% C.I.]
HBV (-) FHF
< 1 Yr 52 25 (0.56)
72 (0.039)
15.2 [8.5, 27.2]
Chang MH
Childhood HCC
1. Male Predominance :
M/F = 3-4 : 1
2. HBV, But Not HCV, Related . HBV, But Not HCV, Related >90% HBsAg Positive, 86% HBeAg >90% HBsAg Positive, 86% HBeAg
Negative, HBV Genome Integration Negative, HBV Genome Integration into Host Genome, 94% Maternal into Host Genome, 94% Maternal HBsAg PositiveHBsAg Positive
Chang MH et al. Hepatology 1991;13:316-Chang MH et al. Hepatology 1991;13:316-2020
Chang MH et al. Cancer 1989; 64: 2377-80Chang MH et al. Cancer 1989; 64: 2377-80
Chang MH
EFFECT OF UNIVERSAL HEPATITIS B EFFECT OF UNIVERSAL HEPATITIS B VACCINATION ON HCC IN VACCINATION ON HCC IN
TAIWANESE CHILDREN, 6-9 YEARSTAIWANESE CHILDREN, 6-9 YEARS Birth HCC Incidence Birth HCC Incidence
Year in ChildrenYear in Children
1974-84 0.52/10 1974-84 0.52/10 55
1984-86 0.13/10 1984-86 0.13/10 55
Chang MH, et al. N Engl Med Chang MH, et al. N Engl Med 1997; 336:1855-9.1997; 336:1855-9.
Chang MH
Incidence of HCC in Children Diagnosed at Aged 6 to 14 Years from July 1981 to June 2000 According to Birth Year
Birth Population No. of Incidence R.R. 95%
Year* Cases (per 10 5) CI
1966-84 48,764,799 263 0.54 1 1984-94 17,817,510 35 0.20 0.36 0.26-0.52 __________________________________________________ * Birth Year was counted from July of one year to June of the next year. R.R.: risk ratio; CI: confidence interval.
Chang MH, et al. Clin Cancer Res 2005;11: 7953-7.
Chang MH Chang MH et al. JAMA2000;284:3040-42
Chang MH
Problems that remain to be solved Problems that remain to be solved for the control of Hepatitis & for the control of Hepatitis & related Diseasesrelated Diseases
Chang MH. Liver International 2003; 23: 309-14.
1. Inadequate Resources
2. Poor Compliance
3. Vaccine Failure
Intrauterine Infection
Genetic Hyporesponsiveness
Vaccine Escape Mutants / Variants
Chang MH
ACKNOWLEDGEMENT ACKNOWLEDGEMENT
1. Hepatitis B Study : Hong-Yuan Hsu, Yen-Hsuan Ni, Huey-Ling Chen,
Chien-Jen Chen, Ding-Shinn Chen
2. Hepatoma Study : Tony Chen, Hsu-Mei Hsu, Tzee-Chung Wu, Man-
Shan Kong, Der-Cherng Liang, Tai-Tsung Chang, Jiann-Shiuh Chen, Chieh-Chung Lin, Fu-Chen Huang, Ming-Tzong Cheng, Chia-Hsian Chu, Su-Fen Wu, Pei-Shin Chang
Chang MH
Thank You Thank You
Very MuchVery Much